Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs

Digestive and Liver Disease

Volumn 43, Issue 3, 2011, Pages 209-214

  Thiéfin, Gérard ^a   Schwalm, Marie Sophie ^b  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b Cegedim Strategic Data ^*  (France)

Author keywords

Gastroduodenal complications; Gastroprotection; NSAID; Observational study; Proton pump inhibitors

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CORTICOSTEROID; DICLOFENAC; ETODOLAC; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; SULINDAC; TENOXICAM; TIAPROFENIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG USE; DYSPEPSIA; FEMALE; FRANCE; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PEPTIC ULCER; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK FACTOR; SPINE DISEASE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DYSPEPSIA; FEMALE; FRANCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 79551489558     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.09.009     Document Type: Article

References (41)

1. Lanas A., Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006, 38:415-428.
2. Larkai E.N., Smith J.L., Lidsky M.D., et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989, 11:158-162.
3. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl 56):18-24.
4. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
5. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, 4:CD002296.
6. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995, 123:241-249.
7. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006, 101:701-710.
8. Chan F.K.L., Chung S.C.S., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
9. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in non-steroidal anti-inflammatory drug users - a randomized trial. Aliment Pharmacol Ther 2003, 18:829-836.
10. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
11. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-1278.
12. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-1626.
13. Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004, 20:321-331.
14. Hernandez-Diaz S., Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099.
15. Weil J., Langman M.J.S., Wainwright P., et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000, 46:27-31.
16. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
17. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123:1006-1012.
18. Aalykke C., Lauritsen J.M., Hallas J., et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999, 116:1305-1309.
19. Hansen J.M., Hallas J., Lauritsen J.M., et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision making. Scand J Gastroenterol 1996, 31:126-130.
20. Moore N., Verschuren X., Montout C., et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000, 55:133-136. [in French].
21. Clinard F., Bardou M., Sgro C., et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 2001, 57:737-743.
22. Clinard F., Sgro C., Bardou M., et al. Non-steroidal anti-inflammatory drug prescribing patterns in general practice: comparison of a general practitoner-based survey and a pharmacy-based survey in France. Pharmacoepidemiol Drug Saf 2001, 10:329-338.
23. Lugardon S., Roussel H., Bourrel R., et al. Patterns of non steroidal anti-inflammatory drug use in ambulatory care. Therapie 2006, 61:109-114. [in French].
24. Sturkenboom M.C., Burke T.A., Dieleman J.P., et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003, 42(Suppl 3):iii23-iii31.
25. Schnitzer T.J., Kong S.X., Mavros P., et al. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 2001, 23:1984-1998.
26. Smalley W.E., Stein C.M., Arbogast P.G., et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002, 46:2195-2200.
27. Hartnell N.R., Flanagan P.S., MacKinnon N.J., et al. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2004, 2:171-180.
28. Abraham N.S., El-Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005, 129:1171-1178.
29. Pilotto A., Franceschi M., Vitale D.F., et al. Upper gastrointestinal symptoms and therapies in elderly outpatients, users of non-selective NSAIDs or coxibs. Aliment Pharmacol Ther 2005, 22:147-155.
30. Recommandations de bonne pratique. Les anti-sécrétoires gastriques chez l'adulte. 2007. Agence Française de Sécurité Sanitaire des Produits de Santé. [accessed 19.01.10]. http://www.afssaps.fr/.
31. Rey E., Elola-Olaso C., Rodriguez-Artalejo F., et al. Use of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general population. Aliment Pharmacol Ther 2006, 24:1585-1592.
32. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2037-2046.
33. Sturkenboom M.C., Burke T.A., Tangelder M.J., et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003, 18:1137-1147.
34. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy of nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
35. van Soest E.M., Sturkenboom M.C., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and hemorrhage. Aliment Pharmacol Ther. 2007, 26:265-275.
36. Singh G., Vadhavkar S., Mithal A., et al. A new safety warning: decreased gastroprotection is associated with an increase of serious ulcer complications in elderly users of NSAIDs. Gut 2007, 56(Suppl 3):A28.
37. Biga J., Gony M., Bourrel R., et al. Coxibs: evolution of prescription's behaviour in France. Fund Clin Pharmacol 2007, 21:317-325.
38. Thiéfin G., Montalescot G., Woimant F., et al. Prevalence of low-dose aspirin treatment in France and concomitant use of gastrotoxic and gastroprotective agents: results of a nation-wide postal survey. Gut 2007, 56(Suppl 3):A230.
39. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
40. Richy F., Bruyere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759-766.
41. Spiegel B.M., Farid M., Dulai G.S., et al. Comparing rates of dyspepsia with coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006, 119:e27-36.